NCT06304961View on ClinicalTrials.gov

A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

September 9, 2024

Study Completion Date

September 9, 2024

Conditions
Healthy Participants
Interventions
BIOLOGICAL

Tozorakimab

Tozorakimab will be administered as a single SC dose on Day 1.

Trial Locations (1)

14050

Research Site, Berlin

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY